Literature DB >> 19324574

Comparisons of the mortality and clinical presentations of status epilepticus in private practice community and university hospital settings in Richmond, Virginia.

Robert J DeLorenzo1, Batool Kirmani, Laxmikant S Deshpande, Vamsy Jakkampudi, Alan R Towne, Elizabeth Waterhouse, Linda Garnett, Viswanathan Ramakrishnan.   

Abstract

We prospectively compared the clinical course of 119 patients treated for status epilepticus (SE) in private practice community hospitals and 344 SE patients treated in the VCU university hospitals in Richmond, Virginia USA over a 2-year period to test the hypothesis that SE presents with the same mortality and clinical patterns in both clinical settings. Of the patients reviewed, the major etiologies for SE were cerebrovascular disease, decreased anti-epileptic drug levels in epileptic patients, anoxia-hypoxia, and remote symptomatic. The other etiologies included were alcohol related, trauma, central nervous system infections, tumors, systemic infection, metabolic disorders, idiopathic, and hemorrhage. These observations provide the first direct prospective comparison of SE present in university and private practice community hospital settings in the same geographic area. Mortality was the highest in the elderly population while the pediatric population had low mortality in both clinical settings. Etiology risk factors for outcome were similar for both the populations. The data also suggest that the higher degree of illness severity in university hospitals may be associated with a higher incidence of SE, but not with mortality or a different clinical presentation of the condition. The results of this study demonstrate that SE has the same mortality and is present in an essentially identical manner in university and private practice community hospitals and underscores the fact that mortality in SE is not just associated with tertiary care hospitals and the importance of recognizing the severity of SE in the private practice setting.

Entities:  

Mesh:

Year:  2009        PMID: 19324574      PMCID: PMC2850102          DOI: 10.1016/j.seizure.2009.02.005

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  19 in total

1.  Causes and consequences of status epilepticus in adults. A study of 86 cases.

Authors:  J M Oxbury; C W Whitty
Journal:  Brain       Date:  1971       Impact factor: 13.501

Review 2.  Status epilepticus: epidemiologic considerations.

Authors:  W A Hauser
Journal:  Neurology       Date:  1990-05       Impact factor: 9.910

3.  Status epilepticus: frequency, etiology, and neurological sequelae.

Authors:  W A Hauser
Journal:  Adv Neurol       Date:  1983

4.  Status epilepticus: the interaction of epilepsy and acute brain disease.

Authors:  E Barry; W A Hauser
Journal:  Neurology       Date:  1993-08       Impact factor: 9.910

5.  Status epilepticus at an urban public hospital in the 1980s.

Authors:  D H Lowenstein; B K Alldredge
Journal:  Neurology       Date:  1993-03       Impact factor: 9.910

6.  In-hospital mortality of generalized convulsive status epilepticus: a large US sample.

Authors:  Mohamad Koubeissi; Amer Alshekhlee
Journal:  Neurology       Date:  2007-08-28       Impact factor: 9.910

7.  Status epilepticus in children, adults, and the elderly.

Authors:  R J DeLorenzo; A R Towne; J M Pellock; D Ko
Journal:  Epilepsia       Date:  1992       Impact factor: 5.864

8.  Status epilepticus. Causes, clinical features and consequences in 98 patients.

Authors:  M J Aminoff; R P Simon
Journal:  Am J Med       Date:  1980-11       Impact factor: 4.965

9.  Convulsive status epilepticus in infants and children. A study of 239 cases.

Authors:  J Aicardi; J J Chevrie
Journal:  Epilepsia       Date:  1970-06       Impact factor: 5.864

10.  Determinants of mortality in status epilepticus.

Authors:  A R Towne; J M Pellock; D Ko; R J DeLorenzo
Journal:  Epilepsia       Date:  1994 Jan-Feb       Impact factor: 5.864

View more
  11 in total

1.  The acute and chronic effects of the novel anticonvulsant lacosamide in an experimental model of status epilepticus.

Authors:  Claude G Wasterlain; Thomas Stöhr; Alain Matagne
Journal:  Epilepsy Res       Date:  2011-01-28       Impact factor: 3.045

Review 2.  Defining the therapeutic time window for suppressing the inflammatory prostaglandin E2 signaling after status epilepticus.

Authors:  Yifeng Du; Timothy Kemper; Jiange Qiu; Jianxiong Jiang
Journal:  Expert Rev Neurother       Date:  2016-01-13       Impact factor: 4.618

3.  Contribution of protease-activated receptor 1 in status epilepticus-induced epileptogenesis.

Authors:  D Isaev; I Lushnikova; O Lunko; O Zapukhliak; O Maximyuk; A Romanov; G G Skibo; C Tian; G L Holmes; E Isaeva
Journal:  Neurobiol Dis       Date:  2015-04-02       Impact factor: 5.996

4.  Development of status epilepticus, sustained calcium elevations and neuronal injury in a rat survival model of lethal paraoxon intoxication.

Authors:  Laxmikant S Deshpande; Dawn S Carter; Kristin F Phillips; Robert E Blair; Robert J DeLorenzo
Journal:  Neurotoxicology       Date:  2014-04-29       Impact factor: 4.294

5.  Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation.

Authors:  Jianxiong Jiang; Yi Quan; Thota Ganesh; Wendy A Pouliot; F Edward Dudek; Raymond Dingledine
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-11       Impact factor: 11.205

6.  Intramuscular atenolol and levetiracetam reduce mortality in a rat model of paraoxon-induced status epilepticus.

Authors:  Laxmikant S Deshpande; Robert E Blair; Matthew Halquist; Leon Kosmider; Robert J DeLorenzo
Journal:  Ann N Y Acad Sci       Date:  2020-09-22       Impact factor: 5.691

7.  Dexmedetomidine stops benzodiazepine-refractory nerve agent-induced status epilepticus.

Authors:  Hilary S McCarren; Julia A Arbutus; Cherish Ardinger; Emily N Dunn; Cecelia E Jackson; John H McDonough
Journal:  Epilepsy Res       Date:  2018-01-31       Impact factor: 3.045

Review 8.  Targeting prostaglandin receptor EP2 for adjunctive treatment of status epilepticus.

Authors:  Marwa M Nagib; Ying Yu; Jianxiong Jiang
Journal:  Pharmacol Ther       Date:  2020-02-21       Impact factor: 13.400

Review 9.  Status Epilepticus: Epidemiology and Public Health Needs.

Authors:  Sebastián Sánchez; Fred Rincon
Journal:  J Clin Med       Date:  2016-08-16       Impact factor: 4.241

Review 10.  Mechanisms of levetiracetam in the control of status epilepticus and epilepsy.

Authors:  Laxmikant S Deshpande; Robert J Delorenzo
Journal:  Front Neurol       Date:  2014-01-31       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.